HSBC has maintained its hold rating on Zydus Life, setting a target price of ₹1,045, which suggests a 10% potential upside from the current market price (CMP) of ₹948.95. The company’s Q2 performance was down sequentially, mainly due to a lack of Revlimid sales, a factor impacting revenue for the quarter.
Despite this, Zydus Life has retained its guidance for revenue and margin targets for FY25, and HSBC notes a healthy near-term outlook for its U.S. sales. However, HSBC remains cautious regarding the competition and concentration risk associated with key products in its portfolio.
Disclaimer: This article is for informational purposes only and should not be considered as financial advice. Please consult a financial advisor before making any investment decisions.
